两种免疫调节剂辅助LAK细胞杀伤喉癌细胞的体外研究

The study of effects of immunologic modifier on proliferation and cytotoxity against HEP 2 of LAK cells in vitro

为探讨如何提高白细胞介素－２（ＩＬ－２）／ＬＡＫ细胞过继免疫治疗的抗肿瘤作用，应用免疫调节剂分枝杆菌多糖（Ｍｙｃｏｂａｃｔｅｒｉａｌｐｏｌｙｓａｃｃｈａｒｉｄｅｓ，ＭＰＳ）或ＣＤ３单克隆抗体协同ＩＬ－２诱导的健康人外周血淋巴细胞来源的ＬＡＫ细胞在体外扩增，测定其对喉癌ＨＥＰ－２细胞杀伤活性。实验结果：①不同免疫调节剂对ＬＡＫ细胞扩增的影响：实验组三组细胞于体外扩增均明显高于对照组（Ｐ＜０．０１）；ＭＰＳ组或ＣＤ３组细胞的扩增倍数比单纯应用ＩＬ－２组为高（Ｐ＜０．０１）；其中扩增倍数最高者为ＭＰＳ组，与ＣＤ３组相比，Ｐ＜０．０５。②不同免疫调节剂诱导的ＬＡＫ细胞对喉癌ＨＥＰ－２细胞的杀伤活性比较：在培养一周时，实验组三组对ＨＥＰ－２细胞的杀伤活性均高于对照组，以ＣＤ３组及ＭＰＳ组杀伤活性最高，其杀伤活性均为５５．５％；于培养第二周，ＣＤ３组杀伤ＨＥＰ－２细胞活性仍较高，其他实验组细胞杀伤活性均明显下降。结论：免疫调节剂ＭＰＳ和ＣＤ３单克隆抗体均可通过增强ＬＡＫ细胞体外增殖和杀瘤活性而提高肿瘤过继免疫治疗效果。

Adoptive immunotherapy as a new approach has been used to treat advanced carcinoma for almost ten years, and gained some good results. However, the application of this method is largely restricted by the side effects along with high dose of IL 2 and lack of sufficient amount of LAK cells. Mycobacterial Polysaccharides (MPS) and anti CD 3 antibodies (CD 3Ab) have been demonstrated to be effective immunologic modifiers capable of proliferating lymphocytes and increasing cytotoxity against tumor cells. In this article we discussed the effects of MPS and CD 3Ab on proliferation and cytotoxity against HEP 2 cells of LAK cells. Our results showed that: ①MPS group ( incubating IL 2 2×10 5/L plus MPS 0.4 mg/L) or CD 3 group (IL 2 1×10 6/L plus CD 3Ab 4 mg/L) were more proliferative than LAK group (only incubated with IL 2 1×10 6/L). MPS group is the most proliferative in the three groups, P <0.05. ②Cytotoxity against HEP 2 in MPS or CD 3 group was also better than in LAK group. CD 3 group could maintain good cytotoxity in the longest period. These results could provide guidance for adoptive immunotherapy assisted by MPS or CD 3Ab.